secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001193125-26-145524
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics appoints Clare Kahn, Ph.D. to Board, increases size to ten
-----------------------------------------------------------------------------

- Board expanded to 10 directors; Kahn appointed as Class I director effective April 3, 2026.
- Kahn receives $45k annual cash retainer and initial option for 30,782 shares (~$724k grant-date value).
- Kahn will chair the R&D Committee and serve on the Nominating & Corporate Governance Committee.
- Kahn brings 30+ years drug development and regulatory experience from X-VAX, Pfizer, and GSK.
- Company is advancing Phase 3 study of zorevunersen for Dravet syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526145524/0001193125-26-145524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526145524/d63742d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-145524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer